Gemcitabine causes and promotes protective signals through transcription factor EB ().
Gemcitabine disrupts DNA replication while also inducing nucleolar stress.
The anticancer agent CX-5461, which is designed to induce nucleolar stress, leads to TFEB accumulating in the nucleus.
Interfering with TFEB enhances the sensitivity of cancer cells to both CX-5461 and gemcitabine.
TFEB is associated with providing protective responses against stress from chemotherapeutic drugs.
Simplified
Identifying mechanisms underlying chemoresistance is essential for improving the efficacy of chemotherapeutic drugs. Previously, we showed that cancer cells respond to gemcitabine by activating protective signals dependent on the master regulator of autophagy and lysosomal biogenesis, transcription factor EB (). However, how gemcitabine triggers these protective responses remains elusive. While gemcitabine primarily aims at disrupting DNA replication, it is also suspected to induce . In this study, we aimed to examine the effect of gemcitabine on nucleolar stress and investigate whether nucleolar stress inducers could trigger TFEB-dependent protective signals. Besides gemcitabine causing nucleolar stress, the anticancer agent CX-5461, primarily designed to induce nucleolar stress, promoted TFEB nuclear accumulation. Interfering with TFEB improved the sensitivity of cancer cells to both CX-5461 and gemcitabine. Our findings suggest that TFEB provides broad protection against the stress caused by chemotherapeutic drugs, representing a promising target for intercepting chemoresistance and improving the efficacy of anticancer agents.
Key numbers
50%
Decrease in clonogenic growth ability
Observed in HeLa and MIA PaCa-2 cells with reduced levels.
60%
Clonogenic growth reduction at highest CX-5461 concentration
Measured in shTFEB cells compared to control at high CX-5461 doses.
Full Text
We can’t show the full text here under this license.